Meeting
2015 ASCO Annual Meeting
Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL).
Authors
Igor Puzanov
Vanderbilt University Medical Center, Nashville, TN
Igor Puzanov , Reinhard Dummer , Jacob Schachter , Anna C. Pavlick , Rene Gonzalez , Paolo Antonio Ascierto , Kim Allyson Margolin , Omid Hamid , Sanjiv S. Agarwala , Matteo S. Carlino , Jochen Utikal , Michal Lotem , Antoni Ribas , Peter Mohr , Charlotte M. Roach , Marisa Dolled-Filhart , Xiaoyun Nicole Li , Scot Ebbinghaus , Soonmo Peter Kang , Adil Daud
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Biomarkers and Correlative Studies from Immunotherapy Trials
Clinical Trial Registration Number
NCT01704287
Citation
J Clin Oncol 33, 2015 (suppl; abstr 3012)
DOI
10.1200/jco.2015.33.15_suppl.3012
Abstract #
3012
Poster Bd #
338
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy.
First Author: Adil Daud
Poster
2023 ASCO Annual Meeting
KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Outcomes in the protocol-specified PD-L1–selected populations.
First Author: Sun Young Rha
Poster
2019 ASCO Annual Meeting
Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.
First Author: Mohammed M. Milhem
Poster
2019 ASCO Annual Meeting
Efficacy and safety of pembrolizumab in patients with advanced adrenocortical carcinoma.
First Author: Nitya Prabhakar Raj